Boston Scientific Co. (NYSE:BSX) Shares Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 14.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 32,646 shares of the medical equipment provider’s stock after acquiring an additional 4,050 shares during the quarter. Ritholtz Wealth Management’s holdings in Boston Scientific were worth $2,916,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its stake in Boston Scientific by 7.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 107,340 shares of the medical equipment provider’s stock valued at $9,588,000 after acquiring an additional 7,618 shares during the period. Redhawk Wealth Advisors Inc. lifted its position in Boston Scientific by 13.3% during the fourth quarter. Redhawk Wealth Advisors Inc. now owns 3,854 shares of the medical equipment provider’s stock valued at $344,000 after purchasing an additional 452 shares during the period. CHURCHILL MANAGEMENT Corp boosted its holdings in Boston Scientific by 0.3% in the fourth quarter. CHURCHILL MANAGEMENT Corp now owns 197,251 shares of the medical equipment provider’s stock valued at $17,618,000 after purchasing an additional 549 shares during the last quarter. Burney Co. grew its position in Boston Scientific by 15.3% during the 4th quarter. Burney Co. now owns 10,192 shares of the medical equipment provider’s stock worth $910,000 after purchasing an additional 1,350 shares during the period. Finally, Wolff Wiese Magana LLC raised its stake in shares of Boston Scientific by 5.9% during the 4th quarter. Wolff Wiese Magana LLC now owns 3,120 shares of the medical equipment provider’s stock valued at $279,000 after buying an additional 175 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares of the company’s stock, valued at $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.6 %

Shares of NYSE BSX opened at $98.73 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $90.79 and a 200 day moving average of $84.33. Boston Scientific Co. has a 12-month low of $59.85 and a 12-month high of $99.14. The stock has a market cap of $145.52 billion, a PE ratio of 81.60, a P/E/G ratio of 2.48 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 earnings per share. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on BSX. Mizuho raised their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Friday, January 10th. Bank of America lifted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Sanford C. Bernstein increased their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Three analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.